$ News

A Look At Day One Biopharmaceuticals (DAWN) Valuation After Recent Share Price Momentum

JP Morgan Downgrades Day One Biopharmaceutical to Neutral, Lowers Price Target to $21.5

This Day One Biopharmaceuticals Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday

Servier’s $2.5B cancer bet underlines a quick oncology growth strategy

HC Wainwright & Co. Downgrades Day One Biopharmaceutical to Neutral, Lowers Price Target to $21.5

DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier

Day One Biopharmaceuticals Touts OJEMDA Sales Surge, Sets $225M-$250M 2026 Outlook at TD Cowen

Wedbush Downgrades Day One Biopharmaceutical to Neutral, Lowers Price Target to $21.5

Day One (DAWN) Soars 100% on $2.5-Billion Merger

Servier’s US$2.5b Deal Caps Day One Biopharma’s Oncology Upside

Day One (DAWN) Climbs to 3-Year High on $2.5-Billion Merger

Stock Market Today, March 6: Energy Stocks Rise as Oil Closes Over $90 on Middle East Tensions

US Equity Indexes Fall Amid Jobs Data Surprise, Rising Oil Prices

Day One Skyrockets On Servier's $2.5 Billion Buyout. Could A 'White Knight' Emerge?

Sector Update: Health Care Stocks Softer Late Afternoon

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio

This Biopharma Company Is Being Bought for $2.5 Billion. Its Stock Is Up 66%.

Jones Trading Downgrades Day One Biopharmaceutical to Hold, Raises Price Target to $21.5

BC-Most Active Stocks

Servier to Buy Day One for $2.5 Billion, Expanding Oncology Portfolio